Achaogen is a clinical stage biopharmaceutical company that focuses on the discovery and development of broad-spectrum antibiotics to counter multidrug resistant bacterial infections. The company provides a range of small molecule therapeutics. It is involved in compound discovery, lead optimization and early-stage clinical trials. Achaogen addresses medical needs that are caused by the development of bacterial resistance to antibiotics. The company maintains a research facility in San Francisco. It receives non-dilutive funding from the Department of Defense and the Welcome Trust. Achaogen has developed ACHN-490 and other neoglycosides to overcome aminoglycoside resistance mechanisms. In addition, the company administers several preclinical programs.